3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
20
Gastrointestinal Stromal Tumors
9
Kidney Neoplasms
6
Breast Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Kidney Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urologic Neoplasms
1
Prostatic Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Patient Preference
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Colorectal Neoplasms
1
Carcinoma, Islet Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Advanced Renal Cancer
1
Adenoma, Islet Cell
1
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
decitabine and cedazuridine drug combination
1
apalutamide
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiotherapy
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Patient Preference
×
Sunitinib
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts